Radiopharmaceutical developer Navidea Biopharmaceuticals has inked an exclusive licensing and distribution agreement with Sayre Therapeutics of Bangalore, India.
Sayre will develop and commercialize Navidea's technetium-99m (Tc-99m) tilmanocept radiopharmaceutical in India. Navidea said it received an upfront payment and will be eligible for upcoming milestone payments and double-digit sales royalties.
The radiopharmaceutical is designed for imaging and intraoperative detection of sentinel lymph nodes draining a primary tumor in adult patients with breast cancer, melanoma, or localized squamous cell carcinoma of the oral cavity, according to the vendor.
